Fig 2. Cost-effectiveness frontier of DAA-treatment strategies among PWID compared to PegIFN/RBVa. Strategy 2: DAA/RBV (G2-3) & dual DAA (g1-4); 3: Dual DAA for all genotypes; 4: Dual DAA with a 3x higher treatment uptake.
a The strategies that fall below the dashed blue line are strategies that fall bellow a willingness to pay threshold reflecting 1 GDP per head of the population, i.e., €38,255 for the Netherlands, and are considered highly cost-effective compared to PegIFN/RBV. However, scenarios are compared incrementally to identify the most cost-effective strategy. The most cost-effective strategy is shown on the “cost-effectiveness frontier”, the line that is closest to the X-axis.